Table 3.
Changes in calcinosis at 1 year compared with baseline based on SCTC radiographic scores and Likert scores
| Patient ID | Disease subtype | Autoantibody | Baseline SCTC radiographic score | Post-treatment SCTC radiographic score | % Change in SCTC radiographic score | Overall change in SCTC radiographic scoreb | Likert score | Length of treprostinil treatment |
|---|---|---|---|---|---|---|---|---|
| 1a | Diffuse | RNA polymerase III | 261.0 | 296.1 | 13.5 | Stabilization | A little better | 12 months |
| 2 | Limited | Anti-centromere | 171.1 | 189.0 | 10.4 | Stabilization | A little better | 1 week |
| 3 | Diffuse | RNA polymerase III | 38.0 | 46.5 | 22.4 | Stabilization | A little better | 12 months |
| 5 | Diffuse | Anti-Scl-70 | 2327.5 | 2844.0 | 22.2 | Stabilization | A little better | 12 months |
| 7 | Diffuse | Anti-centromere | 45.5 | 96.0 | 111.0 | Progression | A little worse | 6 months |
| 8 | Diffuse | Negative | 241.4 | 282.1 | 16.9 | Stabilization | No change | 10 months |
| 9 | Limited | Anti-centromere | 25.0 | 46.9 | 87.5 | Progression | A little worse | 8 months |
| 10 | Limited | Anti-centromere | 14.0 | 22.4 | 59.8 | Progression | No change | 5 months |
| 11 | Limited | Anti-centromere | 126.8 | 232.6 | 83.5 | Progression | No change | 12 months |
| 12 | Diffuse | RNA polymerase III | 241.6 | 147.8 | −38.9 | Improvement | A little better | 5 months |
| 14 | Limited | Anti-centromere | 1314.8 | 1384.5 | 5.3 | Stabilization | No change | 12 months |
a
Patient ID numbers are not all sequential as some patients failed screening and were excluded from the study. Five patients completed the study (patients 1, 3, 5, 11, 14). Patient 6 did not have follow-up radiographs thus was excluded from this table. bProgression (i.e. worsening) of calcinosis was defined as >25% increase in score, improvement as >25% decrease and stabilization (i.e. no change) as values in-between. SCTC: Scleroderma Clinical Trials Consortium.